Methods of determining whether anti-pacap antibodies inhibit pacap-associated photophobia or light aversion

A method of identifying whether a human or humanized antibody or antigen binding fragment that specifically binds to human Pituitary Adenylate Cyclase-Activating Peptide (PACAP) is potentially suitable for use in treating or preventing PACAP-associated photophobia or light aversion, or precluding the onset of PACAP-associated photophobia or light aversion, in a human subject in need thereof, which comprises:

• (i) providing at least one first rodent test subject and at least one second rodent test subject;
• (ii) administering to the at least one first rodent test subject a human or humanized antibody or antigen binding fragment that specifically binds to human PACAP;
• (iii) administering PACAP to the at least one first rodent test subject and the at least one second rodent test subject;
• (iv) comparing the response of the at least one first rodent test subject and at least one second rodent test subject to light;
• and
• (v) based on this comparison, if the first rodent exhibits increased light aversion than the second rodent, thereby identifying that the human or humanized antibody or antigen binding fragment which specifically binds to human PACAP is potentially suitable for precluding the onset of PACAP-associated photophobia or light aversion, in a human subject in need thereof.

A method of identifying whether a human or humanized an antibody or antigen binding fragment that specifically binds to human Pituitary Adenylate Cyclase-Activating Peptide (PACAP) decreases or inhibits light-induced pain signaling through intrinsically photosensitive retinal ganglion cells (“ipRGCs”) in a human subject, which comprises:

• (i) providing at least one first rodent test subject and at least one second rodent test subject;
• (ii) administering PACAP to the first rodent test subject and the second rodent test subject;
• (iii) administering to the first rodent test subject a human or humanized an antibody or antigen binding fragment that specifically binds to human PACAP;
• (iv) comparing the response of the at least one first rodent test subject and at least one second rodent test subject to light;
• and
• (v) based on this comparison, identifying if the human or humanized antibody or antigen binding fragment that specifically binds to human PACAP decreases or inhibits light-induced pain signaling through intrinsically photosensitive retinal ganglion cells (“ipRGCs”);
• and
• (vi) confirming that said human or humanized antibody or antigen binding fragment that specifically binds to human PACAP decreases or inhibits light-induced pain signaling in a human subject.